CD200和CD43表达在慢性淋巴细胞白血病与套细胞淋巴瘤鉴别诊断中的作用
The Role of CD200 and CD43 Expression in Differential Diagnosis between Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma.
作者信息
Falay Mesude, Afacan Öztürk Berna, Güneş Kürşad, Kalpakçı Yasin, Dağdaş Simten, Ceran Funda, Özet Gülsüm
机构信息
University Ministry of Health, Ankara Numune Training and Research Hospital, Clinic of Hematology, Ankara, Turkey.
出版信息
Turk J Haematol. 2018 May 25;35(2):94-98. doi: 10.4274/tjh.2017.0085. Epub 2017 Jul 17.
OBJECTIVE
Atypical chronic lymphocytic leukemia (CLL) is most frequently confused with mantle cell lymphoma (MCL). Several markers may contribute to the diagnosis of CLL. However, there is no consensus on which markers are needed to be used in flow cytometry for the diagnosis of CLL. The aim of the present study was to investigate the role of CD43 and CD200 markers in the differential diagnosis between CLL and MCL.
MATERIALS AND METHODS
To address this issue, 339 consecutive patients with CLL and MCL were included in the flow cytometry lymphoproliferative disease panel for evaluation of CD43 and CD200 expressions, but not in the Matutes scoring system.
RESULTS
CD200 was expressed in 97.3% of atypical CLL cases, whereas it was dimly expressed in only 6.1% of MCL cases. CD43 expression was 95.7% in atypical CLL cases. In the MCL cases, its expression rate was 39.4%.
CONCLUSION
CD43 and CD200 were found to be more valuable markers than CD22, CD79b, and FMC7. CD43 and CD200 could also be considered as definitive markers in atypical CLL patients, for whom the Matutes scoring system remains ineffective.
目的
非典型慢性淋巴细胞白血病（CLL）最常与套细胞淋巴瘤（MCL）相混淆。多种标志物可能有助于CLL的诊断。然而，对于在流式细胞术中诊断CLL需要使用哪些标志物尚无共识。本研究的目的是探讨CD43和CD200标志物在CLL与MCL鉴别诊断中的作用。
材料与方法
为解决这一问题，339例连续的CLL和MCL患者被纳入流式细胞术淋巴增殖性疾病检测组，以评估CD43和CD200的表达情况，但未纳入马图特评分系统。
结果
CD200在97.3%的非典型CLL病例中表达，而在仅6.1%的MCL病例中呈弱阳性表达。非典型CLL病例中CD43表达率为95.7%。在MCL病例中，其表达率为39.4%。
结论
发现CD43和CD200是比CD22、CD79b和FMC7更有价值的标志物。对于马图特评分系统仍然无效的非典型CLL患者，CD43和CD200也可被视为确定性标志物。
Zotero 插件